Approval · Notice of Compliance 4565 · 1996
REVIA: Notice of Compliance 4565
Issued February 28, 1996
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4565
- Date
- February 28, 1996
- Company
- Du Pont Merck Pharma Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New formulation
- Therapeutic class
- Opioid antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REVIA | 02213826 | Marketed |
Medicinal ingredients
- NALTREXONE HYDROCHLORIDE 50 MG per TAB